Non-prescription availability of low-dose codeine products  
https://policybase.cma.ca/link/policy13734

POLICY TYPE  
Response to consultation

DATE  
2017-11-7

TOPICS  
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-45: The Cannabis Act
https://policybase.cma.ca/link/policy13723

POLICY TYPE Parliamentary submission
DATE 2017-08-18
TOPICS Pharmaceuticals, prescribing, cannabis, drugs

Documents
### CMA response to patented medicines regulations consultations

**URL:** [https://policybase.cma.ca/link/policy13690](https://policybase.cma.ca/link/policy13690)

**Policy Type:** Response to consultation  
**Date:** 2017-06-28  
**Topics:** Pharmaceuticals, prescribing, cannabis, drugs

**Documents**

#### Canada’s lower-risk cannabis use guidelines (LRCUG)

**URL:** [https://policybase.cma.ca/link/policy13726](https://policybase.cma.ca/link/policy13726)

**Policy Type:** Policy endorsement  
**Date:** 2017-05-26  
**Topics:** Pharmaceuticals, prescribing, cannabis, drugs

**Documents**
CMA’s Recommendations for Bill S-5: An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts

https://policybase.cma.ca/link/policy13641

POLICY TYPE
Parliamentary submission

DATE
2017-04-07

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA submission to the study of Bill C-37
https://policybase.cma.ca/link/policy13617

POLICY TYPE
Parliamentary submission

DATE
2017-04-06

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission to the study of Bill C-37
An Act to amend the Controlled Drugs and Substances Act and to make related amendments to other Acts

Submission to the Senate Standing Committee on Legal and Constitutional Affairs

April 6, 2017
Consultation on the renewal of Federal Tobacco Control Strategy

https://policybase.cma.ca/link/policy13804

POLICY TYPE
Response to consultation

DATE
2017-04-05

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Regulation of Self-Care Products in Canada

https://policybase.cma.ca/link/policy13802

POLICY TYPE  Response to consultation
DATE  2016-10-31
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

Documents
Statement to the House of Commons Committee on Health addressing the opioid crisis in Canada
https://policybase.cma.ca/link/policy13936

POLICY TYPE Parliamentary submission
DATE 2016-10-18
TOPICS Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health
Health care and patient safety

Documents
Legalization, regulation and restriction of access to marijuana
https://policybase.cma.ca/link/policy11954

POLICY TYPE
Response to consultation

DATE
2016-08-29

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission
Legalization, Regulation and Restriction of Access to Marijuana

Government of Canada – Task Force on Marijuana
Legalization and Regulation

August 29, 2016

STATEMENT | DÉCLARATION

Choi J, et al. - Application of evidence

Evidence: August 9, 2016 - The CMA wishes to ensure that the intent to mobilize a cultural change in Canadian society is matched by the implementation of evidence-based policies for the legalization, regulation and restriction of access to marijuana. The CMA recognizes that the use of marijuana is a complex issue and that there are many factors that must be considered. However, the CMA, based on the available evidence, believes that the legalization of marijuana would have a significant impact on public health and social well-being. The CMA endorses the recommendations put forward by the Task Force on Marijuana Legalization and Regulation. The following recommendations are based on the evidence presented in this submission:

1. The CMA strongly supports the legalization of marijuana for medicinal and recreational use.
2. The CMA recommends the implementation of a formal regulatory framework to ensure the safe and responsible use of marijuana.
3. The CMA recommends the development of education programs to inform the public about the risks and benefits of marijuana.
4. The CMA recommends the implementation of measures to prevent marijuana from being sold to minors.

The CMA believes that these recommendations are crucial for ensuring the safe and responsible use of marijuana. The CMA also recognizes the need for ongoing research and monitoring to assess the impact of these policies on public health and social well-being.

For information: info@cmaj.ca | 613-760-8637

CMA Policybase - Canadian Medical Association
Health Canada’s Consultation on “Plain and Standardized Packaging”
https://policybase.cma.ca/link/policy13817

POLICY TYPE  
Response to consultation

DATE  
2016-08-12

TOPICS  
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents

August 12, 2016

Glen Cooper

Deputy Minister

Public Health Sciences

Health Canada

285 Bank Street

Ottawa, ON

E-mail: Glen Cooper

Canadian Medical Association

Response to Consultation on “Plain and Standardized Packaging”

Canadian governments have been working for decades toward a goal of reducing tobacco use. The goal of the current Consultation to reduce the amount of information on tobacco packaging has focused on reducing awareness of both the health risks and the attractiveness of smoking tobacco. A reduction in both of these factors would contribute to reducing tobacco use in the future.

The Consultation includes a number of requirements for reducing the health risk information on tobacco packaging. The proposed measures would reduce the amount of health and safety information on tobacco packaging to a level that is deemed sufficient by the health authorities. This reduction in information will help to reduce the overall perception of tobacco use, and it will also help to reduce the risk of tobacco use.

The Consultation includes a number of requirements for reducing the attractiveness of tobacco packaging. The proposed measures would reduce the attractiveness of tobacco packaging to a level that is deemed sufficient by the health authorities. This reduction in attractiveness will help to reduce the overall perception of tobacco use, and it will also help to reduce the risk of tobacco use.

The Consultation includes a number of requirements for reducing the health risk information on tobacco packaging. The proposed measures would reduce the amount of health and safety information on tobacco packaging to a level that is deemed sufficient by the health authorities. This reduction in information will help to reduce the overall perception of tobacco use, and it will also help to reduce the risk of tobacco use.

The Consultation includes a number of requirements for reducing the attractiveness of tobacco packaging. The proposed measures would reduce the attractiveness of tobacco packaging to a level that is deemed sufficient by the health authorities. This reduction in attractiveness will help to reduce the overall perception of tobacco use, and it will also help to reduce the risk of tobacco use.

The Consultation includes a number of requirements for reducing the health risk information on tobacco packaging. The proposed measures would reduce the amount of health and safety information on tobacco packaging to a level that is deemed sufficient by the health authorities. This reduction in information will help to reduce the overall perception of tobacco use, and it will also help to reduce the risk of tobacco use.

The Consultation includes a number of requirements for reducing the attractiveness of tobacco packaging. The proposed measures would reduce the attractiveness of tobacco packaging to a level that is deemed sufficient by the health authorities. This reduction in attractiveness will help to reduce the overall perception of tobacco use, and it will also help to reduce the risk of tobacco use.

The Consultation includes a number of requirements for reducing the health risk information on tobacco packaging. The proposed measures would reduce the amount of health and safety information on tobacco packaging to a level that is deemed sufficient by the health authorities. This reduction in information will help to reduce the overall perception of tobacco use, and it will also help to reduce the risk of tobacco use.

The Consultation includes a number of requirements for reducing the attractiveness of tobacco packaging. The proposed measures would reduce the attractiveness of tobacco packaging to a level that is deemed sufficient by the health authorities. This reduction in attractiveness will help to reduce the overall perception of tobacco use, and it will also help to reduce the risk of tobacco use.

The Consultation includes a number of requirements for reducing the health risk information on tobacco packaging. The proposed measures would reduce the amount of health and safety information on tobacco packaging to a level that is deemed sufficient by the health authorities. This reduction in information will help to reduce the overall perception of tobacco use, and it will also help to reduce the risk of tobacco use.

The Consultation includes a number of requirements for reducing the attractiveness of tobacco packaging. The proposed measures would reduce the attractiveness of tobacco packaging to a level that is deemed sufficient by the health authorities. This reduction in attractiveness will help to reduce the overall perception of tobacco use, and it will also help to reduce the risk of tobacco use.
Consultation on the prescription drug list: Naloxone
https://policybase.cma.ca/link/policy11847

POLICY TYPE  Response to consultation
DATE  2016-03-19
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Regulatory framework for the mandatory reporting of adverse drug reactions and medical device incidents by provincial and territorial healthcare institutions.

https://policybase.cma.ca/link/policy11814

POLICY TYPE: Response to consultation
DATE: 2016-01-20
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

Documents
CMA’s Response to Health Canada’s Public Consultation Guide to New Authorities in reference to Bill C-17, Protecting Canadians from Unsafe Drugs Act (Vanessa’s Law)
https://policybase.cma.ca/link/policy11599

POLICY TYPE
Response to consultation

DATE
2015-06-08

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Harms associated with opioids and other psychoactive prescription drugs
https://policybase.cma.ca/link/policy11535

POLICY TYPE  Policy document
DATE       2015-05-30
TOPICS     Pharmaceuticals, prescribing, cannabis, drugs

CMA POLICY

Harms associated with opioids and other psychoactive prescription drugs

Background

Canada has one of the highest rates of prescription opioids in the world, with considerable evidence of overuse and misuse of these drugs. These drugs are often used for chronic pain, and while they can be effective, they can also be addictive and lead to serious health problems. In 2016, the number of opioid-related deaths increased by 75% compared to the previous year, highlighting the need for action.

The Canadian Medical Association (CMA) has published a policy on the use of opioids and other psychoactive prescription drugs, which outlines the potential harms associated with their use. This policy is important in guiding healthcare providers in their prescribing practices and ensuring patient safety.

The CMA encourages healthcare providers to

- Engage in evidence-based prescribing
- Be aware of the harms associated with these drugs
- Discuss the risks and benefits of opioid use with patients
- Implement strategies to manage and reduce the harms associated with these drugs

The policy also recommends other measures to reduce the harms associated with opioids, such as

- Monitoring and evaluating prescribing patterns
- Providing education and training for healthcare providers
- Developing guidelines for the safe use of opioids

The CMA continues to monitor the situation and will update its policies as new information becomes available.

CMA Policybase - Canadian Medical Association
Bill C-2 An Act to amend the Controlled Drugs and Substances Act (Respect for Communities Act)

https://policybase.cma.ca/link/policy11519

POLICY TYPE
Parliamentary submission

DATE
2015-05-14

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-2 An Act to amend the Controlled Drugs and Substances Act (Respect for Communities Act)

https://policybase.cma.ca/link/policy11297

POLICY TYPE
Parliamentary submission

DATE
2014-10-28

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents